IAE-0972 is under clinical development by Sunho (China) Biopharmaceutical and currently in Phase II for Recurrent Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Cancer Squamous Cell Carcinoma have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IAE-0972’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IAE-0972 is under development for the treatment of solid tumors, cutaneous squamous cell carcinoma, squamous non-small cell lung cancer, recurrent or metastatic head and neck squamous cell carcinoma, metastatic colorectal cancer . The drug candidate is administered through intravenous route in the form of injection. It acts by targeting EGFR and IL10.
Sunho (China) Biopharmaceutical overview
Sunho (China) Biopharmaceutical (Sunho (China) Biopharmaceutical) is a healthcare service provider. It specializes in developing drugs for the treatment of cancer. Sunho (China) Biopharmaceutical is headquartered in Chengdu, China.
For a complete picture of IAE-0972’s drug-specific PTSR and LoA scores, buy the report here.